Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys
beta cells of the pancreatic islet, which means that the body can no longer
produce insulin. Over the last 90 years, insulin therapy has been evolving
continuously, as at present, no other treatment can be offered to a patient who
is newly diagnosed with T1D. A variety of insulin analogs with different times
of action - long-acting as well as short or rapid-acting analogs - have been on
the market for the past decade. In addition, many other developments were
happening in parallel, such as glucose monitoring and significant advances in
insulin delivery systems. The T1D market will approximately double over the
forecast period, growing from $6.6 billiion to $13.6 billion.This growth will
be fueled by the significant increase in T1D prevalence as well as the uptake
of the novel ultra-long-acting insulin analogs, novel ultra-rapid formulations
of insulin analogs, and the adjunct therapies for T1D. The launches of these
novel products will offset the dip in sales caused by the patent expiries of
seven insulin products, and the consequent emergence of biosimilars.
Browse Full Research Report With TOC: http://www.radiantinsights.com/research/type-1-diabetes-canada-drug-forecast-and-market-analysis-to-2023
The 2013 base-year market sales of T1D products in Canada were around
$139m. This growth will be fueled by the significant increase in T1D prevalence
in Canada as well as by the uptake of the novel ultra-long-acting insulin
analogs, novel ultra-rapid formulations of insulin analogs, and the adjunct
therapies for T1D. The launches of these novel products will offset the dip in
sales caused by the patent expiries of seven insulin products over the forecast
period.
*This is an on-demand report and will be delivered within 24 hrs.
(excluding weekends) of the purchase.
Scope
- Overview
of T1D including epidemiology, etiology, symptoms, diagnosis, pathology and
treatment guidelines as well as an overview on the competitive landscape.
- Detailed
information on the key drugs in Canada including product T1Dcription, safety
and efficacy profiles as well as a SWOT analysis.
- Sales
forecast for the top drugs in Canada from 2013-2023.
- Analysis
of the impact of key events as well the drivers and restraints affecting Canada
T1D market.
Reasons To Buy
- Understand
and capitalize by identifying products that are most likely to ensure a robust
return
- Stay
ahead of the competition by understanding the changing competitive landscape
for T1D.
- Effectively
plan your M&A and partnership strategies by identifying drugs with the most
promising sales potential
- Make more
informed business decisions from insightful and in-depth analysis of drug
performance
- Obtain
sales forecast for drugs from 2013-2023 in Canada.
See More Reports of This Category by
Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
About
Radiant Insights,Inc
Radiant Insights is a platform for companies looking
to meet their market research and business intelligence requirements. We assist
and facilitate organizations and individuals procure market research reports,
helping them in the decision making process. We have a comprehensive collection
of reports, covering over 40 key industries and a host of micro markets. In
addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
No comments:
Post a Comment